These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17176613)

  • 21. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus and mycophenolate mofetil after liver transplantation.
    Kniepeiss D; Iberer F; Grasser B; Schaffellner S; Tscheliessnigg KH
    Transpl Int; 2003 Jul; 16(7):504-9. PubMed ID: 12687325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in insulin sensitivity after human islet transplantation for type 1 diabetes.
    Rickels MR; Kong SM; Fuller C; Dalton-Bakes C; Ferguson JF; Reilly MP; Teff KL; Naji A
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1780-5. PubMed ID: 24085506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 26. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing.
    Senior PA; Paty BW; Cockfield SM; Ryan EA; Shapiro AM
    Am J Transplant; 2005 Sep; 5(9):2318-23. PubMed ID: 16095517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunossupresive drugs in renal transplantation].
    Baczkowska T; Durlik M
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients.
    Hilbrands R; Huurman VA; Gillard P; Velthuis JH; De Waele M; Mathieu C; Kaufman L; Pipeleers-Marichal M; Ling Z; Movahedi B; Jacobs-Tulleneers-Thevissen D; Monbaliu D; Ysebaert D; Gorus FK; Roep BO; Pipeleers DG; Keymeulen B
    Diabetes; 2009 Oct; 58(10):2267-76. PubMed ID: 19602536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive treatment and progression of histologic lesions in kidney allografts.
    Morales JM
    Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
    Sampaio EL; Pinheiro-Machado PG; Garcia R; Felipe CR; Park SI; Casarini DE; Moreira S; Franco MF; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2008; 22(2):141-9. PubMed ID: 18339132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA; Lawen J; Daley C
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.